Cyclin-dependent kinase 4/6 inhibitors
Cyclin-dependent kinase 4/6 inhibitors are a class of targeted anticancer therapies that block the activity of Cdk4 and CDK6, key regulators of cell-cycle progression from the G1 phase to the S phase.
Cyclin-dependent kinase 4/6 inhibitors are a class of targeted anticancer therapies that block the activity of Cdk4 and CDK6, key regulators of cell-cycle progression from the G1 phase to the S phase. By inhibiting these kinases, the drugs reduce phosphorylation of retinoblastoma pathway components and slow proliferation of tumor cells that depend on cyclin D–Cdk4/6 signaling. In clinical oncology, this mechanism has made Cdk4/6 inhibitors an important component of endocrine-based treatment strategies, especially in hormone receptor-positive, HER2-negative advanced breast cancer.
The best-established clinical role of this drug class is in combination with hormone therapy, where Cdk4/6 inhibitors are used to enhance and prolong disease control. Their use has also prompted investigation into broader biologic effects, including differences in toxicity profiles among agents such as palbociclib and abemaciclib, and potential interactions with immune and inflammatory pathways such as CD274 molecule, the cGAS-STING pathway, and systemic markers like C-reactive protein (CRP). Outside breast cancer, research has explored whether these agents may have activity in other malignancies, although benefits have been more limited in some settings.
Where the papers sit
10 papers from the last 6 months study cyclin-dependent kinase 4/6 inhibitors directly · updated from PubMed 10 Oct 2026
Study type 0 clinical trials · 4 observational · 2 human data · 2 preclinical · 2 unclassified
Themes 3 themes · 1 new direction
-
Real-World Breast Cancer Outcomes
CDK4/6 inhibitor use in HR+/HER2- metastatic breast cancer is being refined through real-world effectiveness, treatment sequencing and individualized prognosis. Older-patient cohorts and Indian clinical experience extend evidence beyond trials, with progression-free survival as a recurring endpoint. Landmark conditional survival reframes prognosis after first-line therapy, while Kaplan–Meier, Cox and machine-learning models seek usable outcome predictions. The remaining question is whether these models and line-by-line recommendations improve selection of subsequent treatment.
5 papers · 50%
-
Breast Cancer Resistance Biology
Resistance to CDK4/6 inhibitors is being traced to epigenetic and cell-cycle escape rather than treated as a single phenotype. SUV39H2 exon skipping may restore sensitivity through transcriptional activation of p21, with SASP accompanying the resistant state. BRCA2 germline alterations bias tumors toward RB1 inactivation, identifying a route that may limit CDK4/6i benefit. The work is moving toward genotype- and mechanism-guided reversal of resistance, but validation across breast cancer subtypes remains open.
2 papers · 20%
-
Others — CDK4/6i Response and Toxicity
Biomarker-defined CDK4/6 inhibitor sensitivity and early treatment toxicity appear together, but they do not form one coherent clinical question. Esophageal squamous cell carcinoma work links inhibition to subtype-specific vulnerability and immune-related responses, whereas LINC01871 is examined as a breast-cancer sensitivity determinant. A separate palbociclib analysis focuses on neutropenia, hepatotoxicity, dose modification and progression-free survival. The shared thread is CDK4/6 inhibitor response and tolerability, with no common mechanism or emerging treatment strategy.
3 papers · 30%
CDK4/6 inhibition can function as an immune-response primer in esophageal squamous cell carcinoma
Palbociclib treatment in treatment-naive esophageal squamous cell carcinoma models showed that CDK4/6 inhibition is not limited to suppressing cell-cycle progression: in delayed responders, it caused DNA-damage accumulation and cGAS-enriched micronuclei, activated interferon-stimulated genes, and increased immune-cell infiltration in vascularized three-dimensional spheroids 42215475May. This introduces an immunomodulatory role for CDK4/6 inhibitors—potentially exposing tumors to immune attack—rather than treating them only as direct antiproliferative agents in the established breast-cancer treatment framework.
Papers
The 10 papers from the last 6 months that study cyclin-dependent kinase 4/6 inhibitors directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Real-World Breast Cancer Outcomes (5)
- Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer. Breast cancer (Tokyo, Japan) · 7 Aug 2026 PMID 42565974
- Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study. Breast cancer research and treatment · 31 Jul 2026 PMID 42536225
- Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer. The oncologist · 10 Jun 2026 PMID 42266036
- Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India. PloS one · 15 May 2026 PMID 42139194
- Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study. Breast (Edinburgh, Scotland) · 28 Apr 2026 PMID 42048902
Breast Cancer Resistance Biology (2)
- Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21. Science advances · 9 Oct 2026 PMID 42853938
- Shaping CDK4/6 Inhibitor Resistance: BRCA2 Germline Alterations Bias toward RB1 Inactivation. Cancer research · 29 Apr 2026 PMID 42054556
Others — CDK4/6i Response and Toxicity (3)
- Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786218
- LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer. Journal of visualized experiments : JoVE · 9 Sept 2026 PMID 42714000
- CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475
By study type
Observational studies and case reports (4)
- Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786218
- Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer. Breast cancer (Tokyo, Japan) · 7 Aug 2026 PMID 42565974
- Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study. Breast cancer research and treatment · 31 Jul 2026 PMID 42536225
- Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India. PloS one · 15 May 2026 PMID 42139194
Human data, design not indexed (2)
- Shaping CDK4/6 Inhibitor Resistance: BRCA2 Germline Alterations Bias toward RB1 Inactivation. Cancer research · 29 Apr 2026 PMID 42054556
- Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study. Breast (Edinburgh, Scotland) · 28 Apr 2026 PMID 42048902
Preclinical: animal, cell and lab studies (2)
- Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21. Science advances · 9 Oct 2026 PMID 42853938
- LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer. Journal of visualized experiments : JoVE · 9 Sept 2026 PMID 42714000
Unclassified: not yet indexed with MeSH (2)
- Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer. The oncologist · 10 Jun 2026 PMID 42266036
- CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.